Listed

Relmada Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2018

Filed with the SEC on May 14, 2018 and accepted by EDGAR at May 14, 2018, 16:32 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2018-01-01 to 2018-03-31$1.7mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2017-07-01 to 2018-03-31$2.0mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2018-01-01 to 2018-03-31−$2.5mus-gaap:OperatingIncomeLoss
Operating income9 months2017-07-01 to 2018-03-31−$5.0mus-gaap:OperatingIncomeLoss
Net income3 months2018-01-01 to 2018-03-31−$3.2mus-gaap:NetIncomeLoss
Net income9 months2017-07-01 to 2018-03-31−$5.6mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-01-01 to 2018-03-31−$0.26us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2017-07-01 to 2018-03-31−$0.45us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2017-07-01 to 2018-03-31−$3.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2017-07-01 to 2018-03-31$2.6kus-gaap:PaymentsToAcquireProductiveAssets
Cash and equivalentsAt period end2018-03-31$4.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-03-31$4.5mus-gaap:AssetsCurrent
Total assetsAt period end2018-03-31$4.8mus-gaap:Assets
Current liabilitiesAt period end2018-03-31$5.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-03-31$7.1mus-gaap:Liabilities
Shareholders' equityAt period end2018-03-31−$2.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-18-006121. Last ingested by Listed: Nov 13, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.